Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a $257 million Series D financing co--led by investment funds managed by BlackRock and Eclipse, ...
Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the ...
With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, ...
Cellares, an Integrated Development and Manufacturing Organization (IDMO), announced a $257 million Series D financing co‑led ...
Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell ...
AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...
FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and gene therapies.
Market OverviewThe global cell and gene therapy market is undergoing rapid and transformative growth, reflecting its increasing importance in modern healthcare.The market is projected to expand at a ...
Raw materials play a critical role in cell therapy manufacturing. Choosing suboptimal materials at any stage of development ...
To evaluate the potential for applying GMP-ready robotic systems to commercial-scale cell therapy manufacturing.
Multiply Labs' goal is to enable scalable, high-throughput manufacturing while maintaining rigorous quality and regulatory standards.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results